PLYMOUTH MEETING, Pa.,
April 27, 2021 /PRNewswire/
-- INOVIO (NASDAQ: INO) announced today that first quarter
2021 financial results will be released after the market close on
May 10, 2021. Following the release,
INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and
provide a general business update regarding its DNA Medicines
Platform, including the company's ongoing vaccine developments for
COVID-19.
A live and archived version of the audio presentation will be
available online at
http://ir.inovio.com/events-and-presentations/default.aspx. This is
a listen-only event but will include a live Q&A with
analysts.
About INOVIO
INOVIO is a biotechnology company focused on rapidly bringing to
market precisely designed DNA medicines to treat and protect people
from infectious diseases, cancer, and diseases associated with HPV.
INOVIO is the first and only company to have
clinically demonstrated that a DNA medicine can be delivered
directly into cells in the body via a proprietary smart device to
produce a robust and tolerable immune response. Specifically,
INOVIO's lead candidate VGX-3100 is the first DNA medicine to
achieve efficacy endpoints in a Phase 3 clinical trial, REVEAL 1,
for the treatment of precancerous cervical dysplasia caused by
HPV-16 and/or HPV-18. VGX-3100 also demonstrated positive Phase 2
efficacy results in separate trials evaluating the treatment of
precancerous vulvar dysplasia and anal dysplasia. Also in
development are programs targeting HPV-related cancers and a rare
HPV-related disease, recurrent respiratory papillomatosis (RRP);
non-HPV-related cancers glioblastoma multiforme (GBM) and prostate
cancer; as well as externally funded infectious disease DNA vaccine
development programs in Zika, Lassa fever, Ebola, HIV, and
coronaviruses associated with MERS and COVID-19 diseases. Partners
and collaborators include Advaccine, ApolloBio Corporation,
AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for
Epidemic Preparedness Innovations (CEPI), Defense Advanced Research
Projects Agency (DARPA)/Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense
(JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial
Network, International Vaccine Institute (IVI), Kaneka Eurogentec,
Medical CBRN Defense Consortium (MCDC), National Cancer Institute,
National Institutes of Health, National Institute of Allergy and
Infectious Diseases, Ology Bioservices, the Parker Institute
for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron,
Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army
Institute of Research, and The Wistar Institute. INOVIO also is a
proud recipient of 2020 Women on Boards "W" designation recognizing
companies with more than 20% women on their board of directors. For
more information, visit www.inovio.com.
CONTACTS:
Investors:
Ben Matone, 484-362-0076,
ben.matone@inovio.com
Media:
Jeff Richardson, 267-440-4211,
jrichardson@inovio.com
View original
content:http://www.prnewswire.com/news-releases/inovio-to-report-first-quarter-2021-financial-results-on-may-10-2021-301277656.html
SOURCE INOVIO Pharmaceuticals, Inc.